- Report
- February 2021
- 360 Pages
United States
From €2306EUR$2,400USD£1,972GBP
- Report
- February 2019
- 105 Pages
Global
From €1239EUR$1,290USD£1,060GBP
- Report
- February 2024
- 73 Pages
Global
From €3500EUR$3,902USD£3,097GBP
- Report
- September 2022
- 89 Pages
Global
From €3363EUR$3,500USD£2,875GBP
- Drug Pipelines
- April 2019
- 85 Pages
Global
From €3363EUR$3,500USD£2,875GBP
- Report
- May 2024
- 50 Pages
Global
From €2546EUR$2,650USD£2,177GBP
- Report
- November 2021
- 620 Pages
Global
From €3843EUR$4,000USD£3,286GBP
Maraviroc is a drug used to treat immune disorders, such as HIV and AIDS. It is a CCR5 antagonist, meaning it blocks the CCR5 receptor on the surface of certain immune cells, preventing the virus from entering the cells. Maraviroc is used in combination with other antiretroviral drugs to treat HIV infection. It is also used to treat other immune disorders, such as rheumatoid arthritis and multiple sclerosis. Maraviroc is available in both oral and intravenous forms.
Maraviroc is a relatively new drug, having been approved by the US Food and Drug Administration in 2007. It is a popular choice for treating HIV and AIDS due to its effectiveness and relatively low side effects.
Several companies are involved in the Maraviroc market, including ViiV Healthcare, Merck, and Gilead Sciences. ViiV Healthcare is the manufacturer of the drug, while Merck and Gilead Sciences are involved in the research and development of new treatments for HIV and AIDS. Show Less Read more
